Latest seizures Stories
WOODCLIFF LAKE, N.J., Feb.
-- Results of Investigational Studies of Perampanel and Rufinamide Accepted as Late-Breaking Posters -- WOODCLIFF LAKE, N.J., Dec. 5, 2014 /PRNewswire/ -- Eisai Inc.
Company partners with the Epilepsy Foundation to help improve the lives of those living with epilepsy CAMBRIDGE, Mass. and MILAN, Nov.
A new statistical test that looks at the patterns of high-frequency network activity flow from brain signals can help doctors pinpoint the exact location of seizures occurring in the brain and
Findings Presented at 43rd Annual Meeting of the Child Neurology Society MAPLE GROVE, Minn., Oct.
Head growth significantly improved in placebo-controlled trial MOUNTAIN VIEW, Calif., Sept.
- VIMPAT® (lacosamide) C-V approved in the U.S. as monotherapy in the treatment of partial-onset seizures in adults with epilepsy(1) BRUSSELS, Sept.
Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S.
LONDON, July 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: